Monitoring anticoagulation with argatroban in critically ill patients: activated partial thromboplastin time versus diluted thrombin time

Cornelius Keyl; Cornelius Lehane; Emanuel Zimmer; Dietmar Trenk

doi:10.1160/TH16-06-0468

Subscribe to RSS

Please copy the URL and add it into your RSS Feed Reader.

https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00035024.xml

Share / Bookmark

Facebook X Linkedin Weibo

Download PDF

Thromb Haemost 2016; 116(06): 1180-1181
DOI: 10.1160/TH16-06-0468

Letter to the Editor

Schattauer Publishers Schattauer

Monitoring anticoagulation with argatroban in critically ill patients: activated partial thromboplastin time versus diluted thrombin time

Cornelius Keyl

¹Department of Anaesthesiology, University Heart Centre Freiburg – Bad Krozingen, Bad Krozingen, Germany

,

Cornelius Lehane

¹Department of Anaesthesiology, University Heart Centre Freiburg – Bad Krozingen, Bad Krozingen, Germany

,

Emanuel Zimmer

²Department of Cardiovascular Surgery, University Heart Centre Freiburg – Bad Krozingen, Bad Krozingen, Germany

,

Dietmar Trenk

³Department of Clinical Pharmacology, University Heart Centre Freiburg – Bad Krozingen, Bad Krozingen, Germany

› Author Affiliations

Further Information

Publication History

Received: 23 June 2016

Accepted after minor revision: 23 August 2016

Publication Date:
09 March 2018 (online)

Also available at

Abstract
PDF (171 kb)
References

PDF Download Buy Article Permissions and Reprints

References
1 Linkins LA, Dans AL, Moores LK. et al. Treatment and prevention of heparin-induced thrombocy-topenia: Antithrombotic therapy and prevention of thrombosis, 9th ed: American college of chest physicians evidence-based clinical practice guidelines. Chest 2012; 141: e495S-530S.

Crossref PubMed Search in Google Scholar
2 Alatri A, Armstrong AE, Greinacher A. et al. Results of a consensus meeting on the use of argatro-ban in patients with heparin-induced thrombocy-topenia requiring antithrombotic therapy - a european perspective. Thromb Res 2012; 129: 426-433.

Crossref PubMed Search in Google Scholar
3 Lewis BE, Wallis DE, Berkowitz SD. et al. Argatro-ban anticoagulant therapy in patients with hepa-rin-induced thrombocytopenia. Circulation 2001; 103: 1838-1843.

Crossref PubMed Search in Google Scholar
4 Fenyvesi T, Jorg I, Harenberg J. Monitoring of anticoagulant effects of direct thrombin inhibitors. Semin Thromb Hemost 2002; 28: 361-368.

Thieme Connect PubMed Search in Google Scholar
5 Francis JL, Hursting MJ. Effect of argatroban on the activated partial thromboplastin time: A comparison of 21 commercial reagents. Blood Coagul Fibrinolysis 2005; 16: 251-257.

Crossref PubMed Search in Google Scholar
6 Love JE, Ferrell C, Chandler WL. Monitoring direct thrombin inhibitors with a plasma diluted thrombin time. Thromb Haemost 2007; 98: 234-242.

Thieme Connect PubMed Search in Google Scholar
7 Warkentin TE. Anticoagulant failure in coagulo-pathic patients: PTT confounding and other pitfalls. Expert Opin Drug Saf 2014; 13: 25-43.

Crossref PubMed Search in Google Scholar
8 Guy S, Kitchen S, Maclean R. et al. Limitation of the activated partial thromboplastin time as a monitoring method of the direct thrombin inhibitor argatroban. Int J Lab Hematol 2015; 37: 834-843.

Crossref PubMed Search in Google Scholar
9 Smythe MA, Forsyth LL, Warkentin TE. et al. Progressive, fatal thrombosis associated with heparin-induced thrombocytopenia after cardiac surgery despite Ȝtherapeutic” anticoagulation with argatro-ban: Potential role for PTT and ACT confounding. J Cardiothorac Vasc Anesth 2015; 29: 1319-1321.

Crossref PubMed Search in Google Scholar
10 Keyl C, Zimmer E, Bek MJ. et al. Argatroban phar-macokinetics and pharmacodynamics in critically ill cardiac surgical patients with suspected hepa-rin-induced thrombocytopenia. Thromb Haemost 2016; 115: 1081-1089.

Thieme Connect PubMed Search in Google Scholar
11 Akimoto K, Klinkhardt U, Zeiher A. et al. Antico-agulation with argatroban for elective percutaneous coronary intervention: Population phar-macokinetics and pharmacokinetic-pharmacody-namic relationship of coagulation parameters. J Clin Pharmacol 2011; 51: 805-818.

Crossref PubMed Search in Google Scholar
12 Walenga JM. An overview of the direct thrombin inhibitor argatroban. Pathophysiol Haemost Thromb 2002; 32 (Suppl. 03) 9-14.

PubMed Search in Google Scholar
13 Gosselin RC, King JH, Janatpour KA. et al. Comparing direct thrombin inhibitors using aPTT, eca-rin clotting times, and thrombin inhibitor management testing. Ann Pharmacother 2004; 38: 1383-1388.

Crossref PubMed Search in Google Scholar
14 Castellone DD, Van Cott EM. Laboratory monitoring of new anticoagulants. Am J Hematol 2010; 85: 185-187.

PubMed Search in Google Scholar
15 Schaden E, Schober A, Hacker S. et al. Ecarin modified rotational thrombelastometry: A point-of-care applicable alternative to monitor the direct thrombin inhibitor argatroban. Wien Klin Wo-chenschr 2013; 125: 156-159.

Crossref PubMed Search in Google Scholar
16 Lind SE, Boyle ME, Fisher S. et al. Comparison of the aPTT with alternative tests for monitoring direct thrombin inhibitors in patient samples. Am J Clin Pathol 2014; 141: 665-674.

Crossref PubMed Search in Google Scholar
17 Curvers J, van de Kerkhof D, Stroobants AK. et al. Measuring direct thrombin inhibitors with routine and dedicated coagulation assays: Which assay is helpful?. Am J Clin Pathol 2012; 138: 551-558.

Crossref PubMed Search in Google Scholar
18 Wanat MA, Hart SR, Putney D. et al. Alternative monitoring of argatroban using plasma-diluted thrombin time. Ann Pharmacother 2013; 47: e18.

Crossref PubMed Search in Google Scholar

Subscribe to RSS

Share / Bookmark

Monitoring anticoagulation with argatroban in critically ill patients: activated partial thromboplastin time versus diluted thrombin time

Publication History

References